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Abstract: NMR-based metabolomics investigations of human biofluids offer great potential to
uncover new biomarkers. In contrast to protocols for sample collection and biobanking, procedures
for sample preparation prior to NMR measurements are still heterogeneous, thus compromising the
comparability of the resulting data. Herein, we present results of an investigation of the handling of
cerebrospinal fluid (CSF) samples for NMR metabolomics research. Origins of commonly observed
problems when conducting NMR experiments on this type of sample are addressed, and suitable
experimental conditions in terms of sample preparation and pH control are discussed. Sample
stability was assessed by monitoring the degradation of CSF samples by NMR, hereby identifying
metabolite candidates, which are potentially affected by sample storage. A protocol was devised
yielding consistent spectroscopic data as well as achieving overall sample stability for robust analysis.
We present easy to adopt standard operating procedures with the aim to establish a shared sample
handling strategy that facilitates and promotes inter-laboratory comparison, and the analysis of
sample degradation provides new insights into sample stability.
Keywords: cerebrospinal fluid; CSF; NMR metabolomics; sample preparation; pH; sample
degradation; time and temperature dependence; standard operating procedures; SOP
1. Introduction
Cerebrospinal fluid (CSF), a secretion product of the central nervous system (CNS), is in dynamic
exchange with the nerve tissue and circulates metabolites. Its composition indirectly reflects the
biochemical processes occurring in the brain [1]. More recently, CSF metabolomics has received much
attention in the research of neurological disorders like Alzheimer’s, Parkinson’s disease, multiple
sclerosis or brain injury, amongst others [2–8].
NMR spectroscopic analysis of CSF in the field of metabolomics has gained importance due to the
minimal requirement for sample preparation, and its ability to simultaneously detect and quantify a wide
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range of compounds. A fairly simple composition, low lipid and protein content [9–11]—compared
to biofluids like blood or urine—make CSF an ideal candidate for NMR analysis, and indeed,
its feasibility was demonstrated some thirty years ago [12]. Yet, handling of CSF samples still
remains challenging [13] and some practical issues related to sampling procedure and sample stability,
particularly pH control [14], require special attention.
Standardized collection of CSF and biobanking protocols have been established benefitting from
clinical environments [15–17], but study-specific CSF sample preparation procedures at different
research facilities prior to NMR spectroscopic analysis vary in key steps of the procedures. This is a
critical aspect because variance introduced by sample preparation needs to be kept at a minimum to
allow for comparability of results: NMR spectral features such as a signal-to-noise ratio, metabolite
peak position (resonance frequency) and line shapes are affected by physiochemical parameters, thereby
impacting compound identification and quantification accuracy.
The reported procedures in the literature differ in sample handling (e.g., storage
duration/temperature), native sample volume, constitution (e.g., lyophilized samples) and final
composition (e.g., sample/buffer-ratio). Remarkably, pre-analytical factors such as sample pH and
ionic strength, native sample dilution, and treatment of high-molecular weight compounds differed
amongst the consulted research articles, suggesting the lack of a common and comprehensive strategy,
although it would be highly desirable.
We hereby propose a standard operating procedure designed to mitigate the influences of
the aforementioned pre-analytical factors and present an efficient and simplified protocol for CSF
sample preparation for NMR analysis. The presented protocol has been evaluated by analyzing
authentic human CSF samples under the aspect of pH and (thereby) proton chemical shift consistency,
and overall sample stability. Degradation was monitored in a two-sided scheme representing routine
NMR laboratory conditions (i.e., experimental temperature and acquisition/waiting time).
2. Results and Discussion
A careful review of sample preparation procedures for the analysis of CSF samples by NMR
spectroscopy described in the literature revealed that a large variety of protocols were adopted in the
last fifteen years (Table 1) [4–8,13,18–39]. We have investigated the reliability of a self-designed protocol
for the preparation of CSF samples, which enables the acquisition of NMR data compatible with small
molecules spectra libraries used for NMR metabolomic profiling, thus preventing data misinterpretation.
Since CSF sample stability as well as interpretability of spectral data (i.e., chemical shift values)
depend mainly on pH and, to a lesser extent, on osmolality and ionic strength, we have mainly
focused on different aspects of pH control of CSF samples. In contrast to the substantial buffer
capacity existing in blood/plasma, for example, the only acid-base homeostatic mechanism in CSF
is a (native) bicarbonate buffer system. Immediately after sampling and exposure to an atmosphere
with a non-physiological level of CO2, CSF is highly prone to undergo changes in pH [40,41]. A rising
pH is the consequence, leading to decreased stability of metabolites sensitive to pH changes and,
in addition, chemical shift changes that impede data analysis. In the reviewed literature, we did not
find general agreement about protocol (experimental conditions), or optimal pH values for NMR-based
metabolomics studies of CSF. Some studies did not report or adjust sample pH [8,23,24,26,32,35],
while others manually adjusted it by adding acid/base [4,7,19,28,29,35,37] or employed a phosphate
buffer with varying buffer capacity [5,6,13,18,20,21,25,27,31,33,34,38,39].
Metabolites 2020, 10, 251 3 of 15
Table 1. Pre-analytical factors and common steps in NMR sample preparation for metabolomic analysis
of cerebrospinal fluid (CSF) described in the literature) [4–8,13,18–39].
Pre-Analytical Factor Preparation Step Conditions
Sample Volume
Variations of native sample volume.
Sometimes native samples are lyophilized
[22,31,36,42] and reconstituted and/or
diluted [22,31,36,42–44].
Available native CSF volume ranges from
40–570 µL. Depending on experimental
setup/objective, samples may be
reconstituted/diluted with H2O/D2O.
Ionic Strength Ionic strength buffering is rarelyaddressed [5,6,21,38].
Osmotic properties of buffer solutions
vary (combinations of sodium/potassium
phosphates/chlorides at
varying concentrations)
Sample pH
Either adjusted with buffer solution
[5,6,13,18,20,21,25,27,31,33,34,38,39],
by adding HCl/NaOH solution
[4,7,19,28,29,35,37], or ignored
[8,23,24,26,32,36].
Adjusted sample pH range from 2.5–10.
Buffer solutions with sodium/potassium
phosphate concentration in the range of
35–166 mM.
Sample Solution Homogeneity
Mixing, centrifugation [4,6,7,26,38]
and filtration [19,28,29,37] in order to
homogenize samples and remove high
MW compounds and cellular material.
Vortexing, mixing (e.g., by inversion),
centrifugation, filtering,
and deproteinization by precipitation
are found.
Chemical Shift Reference and
Internal Standard Lock Signal
TSP-d4 or DSS(-d6). Samples contain
between 10% and 100% D2O as
lock standard.
Typical concentration of reference
compound is 0.5–1.25 mM in the final
sample. Deuterated solvent is either used
for reconstitution, as part of buffer
solution, or added separately.
Storage and Stability
After preparation, while queued for
acquisition, samples are stored under
suitable conditions to maintain
sample integrity.
Samples were either frozen (253 K) [45],
typically stored in a cooled (277–279 K)
environment [37,38,46], or sometimes
kept at ambient temperature (294 K) [47].
We prepared first a model solution containing 13 common CSF metabolites (see Materials and
Methods, and Figure S1, Supplementary Materials) and investigated aspects of pH control and buffer
performance. Spectra of the model solution at different pH values were recorded to explore the
influence of pH on spectral properties of CSF metabolites. In this way, an optimal pH for work with
authentic CSF samples was defined. When taking the specificities of CSF into consideration, employing
a buffer offers the only sustained pH control. Different literature-reported phosphate buffer ratios
and compositions were tested using the model solution. A phosphate buffer system H2PO4−/HPO42−
(pKa 6.8) with an ideal buffer capacity in the pH range of 5.8–7.8 is well suited for pH control in CSF
samples—native human CSF has a pH of 7.3. Adjusting buffer pH to a slightly lower value, pH 7.2,
compensates for inter-sample pH variability and keeps the pH of samples in the range of native
CSF [33,48]. In Figure 1 the 1D 1H NMR spectra of a CSF sample at pH 7.48 along with two spectra
of the model solution at different pH values are shown demonstrating the impact of a pH increase
(e.g., as a result of improper handling of a native CSF sample).
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of His, Phe, Tyr, Gln, Ala and Thr. TMX/XAN = xanthine/caffeine (tentative assignments, see 
Supplementary Materials for discussion), Ala† = Alanine + unknown, * = lactate 13C satellite, 
Lac‡ = lactate + Thr, unk = unknown. Note: For compound abbreviations see Table 2. 
Initially we used, as previously reported in the literature [49,50], an internal pH indicator 
(i.e., imidazole) to monitor sample pH, thus avoiding individual measurements with a glass pH 
electrode, and also preventing potential sample contamination in this process. However, the 
results were not as accurate as expected, and the potential of overlapping signals of imidazole 
with a number of metabolite signatures in the aromatic region (e.g., if added with the buffer) 
led us to abandon this strategy. Instead, we measured the pH of the NMR samples after 
recording of spectra with a pH electrode for NMR tubes (Supplementary Materials Figure S2) 
to monitor buffer performance. 
Furthermore, cation binding/complexation and ionic strength were identified to be 
important. A non-negligible correlation between chemical shifts, as well as peak shapes of some 
metabolites (e.g., citrate, glutamine and glucose) and osmolality was reported in an earlier 
study [48]. The buffer solution selected by us, consisting of mixed sodium and potassium 
phosphate salts, accounts for total sodium and potassium concentration without (additional) 
need to add corresponding chloride salts. An increased buffer volume accommodates varying 
concentration ranges of ionic species, e.g., lowering overall concentration of Ca2+ in solution 
while avoiding an excess of Na+, both known to affect peak shapes and chemical shifts [51,52]. 
In agreement with a previous study [49], our findings suggest that there is no need for 
protein removal to eliminate a broad signal underground (i.e., signals from macromolecular 
compounds), either by centrifugation, filtration or precipitation. Sample concentration by 
lyophilization should also be avoided if possible. It possibly only offers benefits for small 
sample volumes, is time consuming and prone to introducing quantitation uncertainties (e.g., 
side reactions [3] and loss of volatile metabolites [3,53]). 
For metabolite identification and quantitation, a reference compound at a known 
concentration, either DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) or TSP (sodium 
3-trimethylsilylpropanoate), is commonly added. DSS is known to be less affected by low pH 
values and higher protein concentrations [54], both not common in CSF. Therefore, we 
recommend the use of TSP-d4, which is significantly less costly. Possibly out of cost restraints 
some studies used non-deuterated DSS [49,50]. Such practice should be discouraged because of 
resulting peak overlap in the chemical shift region of aliphatic compounds hampering 
identification and quantification. 
Taking all these aspects into consideration, we envisioned a protocol for the preparation of 
CSF samples, which was further validated. An illustration of the whole procedure is shown in 
Figure 2. 
Figure 1. Partial one-dimensional 1H NMR spectra of the model solution (a,c) and an authentic CSF
sample (b). The impact of a rise in pH can be clearly seen following the resonance positions of His, Phe,
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Tyr, Gln, Ala and Thr. TMX/XAN = xanthine/caffeine (tentative assignments, see Supplementary
Materials for discussion), Ala† = Alanine + unknown, * = lactate 13C satellite, Lac‡ = lactate + Thr,
unk = unknown. Note: For compound abbreviations see Table 2.
Table 2. List of metabolites and concentrations (µM) determined in one of the pooled CSF samples
(i.e., LT = low temperature pooled sample, see text).
Entry Compound Code Concentration (µM)
1 2-Hydroxybutyrate aHBA 18.4 ± 0.9
2 2-Hydroxyisovalerate bHMB 4.4 ± 0.2
3 Acetate AA 34.3 ± 1.7
4 Acetoacetate AcA 4.3 ± 0.2
5 Acetone Ac 7.4 ± 0.4
6 Alanine Ala 25.2 ± 1.3
7 Ascorbate AacA 109.9 ± 5.5
8 Caffeine TMX 9.7 ± 0.5
9 Choline CHO 2.3 ± 0.1
10 Citrate Cit 90.9 ± 0.4
11 Creatine Cr 27 ± 1.4
12 Creatinine Cre 55.1 ± 2.8
13 Dimethylamine DMA 1.5 ± 0.1
14 Dimethyl sulfone DMS 7.2 ± 0.4
15 Ethanol EtOH 1934.8 ± 96.7
16 Formate FA 19.3 ± 1.0
17 Fructose Frc 130.2 ± 6.5
18 Glucose Glc 2013.3 ± 100.7
19 Glutamine Gln 246.0 ± 12.3
20 Glycine Gly 5.5 ± 0.3
21 Histidine His 8.2 ± 0.4
22 Hypoxanthine HX 3.7 ± 0.2
23 Isoleucine Ile 3.5 ± 0.2
24 Isopropanol iPrOH 224.1 ± 11.2
25 Lactate Lac 907.7 ± 45.4
26 Leucine Leu 7.8 ± 0.4
27 Lysine Lys 16.2 ± 0.8
28 Mannose Man 28.6 ± 1.4
29 Methanol MeOH 45.4 ± 2.3
30 myo-Inositol MIOL 66.3 ± 3.3
31 Phenylalanine Phe 5.7 ± 0.3
32 Pyroglutamate pyGlu 12.8 ± 0.6
33 Pyruvate Pyr 12.8 ± 0.6
34 Threonine Thr 31.0 ± 1.6
35 Trimethylamine N-oxide TMAO 1.2 ± 0.1
36 Tyrosine Tyr 8.2 ± 0.4
37 Valine Val 11.1 ± 0.6
38 Xanthine XAN 4.5 ± 0.2
Initially we used, as previously reported in the literature [49,50], an internal pH indicator
(i.e., imidazole) to monitor sample pH, thus avoiding individual measurements with a glass pH
electrode, and also preventing potential sample contamination in this process. However, the results
were not as accurate as expected, and the potential of overlapping signals of imidazole with a number
of metabolite signatures in the aromatic region (e.g., if added with the buffer) led us to abandon this
strategy. Instead, we measured the pH of the NMR samples after recording of spectra with a pH
electrode for NMR tubes (Supplementary Materials Figure S2) to monitor buffer performance.
Furthermore, cation binding/complexation and ionic strength were identified to be important.
A non-negligible correlation between chemical shifts, as well as peak shapes of some metabolites
(e.g., citrate, glutamine and glucose) and osmolality was reported in an earlier study [48]. The buffer
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solution selected by us, consisting of mixed sodium and potassium phosphate salts, accounts for total
sodium and potassium concentration without (additional) need to add corresponding chloride salts.
An increased buffer volume accommodates varying concentration ranges of ionic species, e.g., lowering
overall concentration of Ca2+ in solution while avoiding an excess of Na+, both known to affect peak
shapes and chemical shifts [51,52].
In agreement with a previous study [49], our findings suggest that there is no need for protein
removal to eliminate a broad signal underground (i.e., signals from macromolecular compounds),
either by centrifugation, filtration or precipitation. Sample concentration by lyophilization should also
be avoided if possible. It possibly only offers benefits for small sample volumes, is time consuming
and prone to introducing quantitation uncertainties (e.g., side reactions [3] and loss of volatile
metabolites [3,53]).
For metabolite identification and quantitation, a reference compound at a known concentration,
either DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) or TSP (sodium 3-trimethylsilylpropanoate),
is commonly added. DSS is known to be less affected by low pH values and higher protein
concentrations [54], both not common in CSF. Therefore, we recommend the use of TSP-d4, which is
significantly less costly. Possibly out of cost restraints some studies used non-deuterated DSS [49,50].
Such practice should be discouraged because of resulting peak overlap in the chemical shift region of
aliphatic compounds hampering identification and quantification.
Taking all these aspects into consideration, we envisioned a protocol for the preparation of CSF
samples, which was further validated. An illustration of the whole procedure is shown in Figure 2.
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D2OBuffer
(I) Thawing at ambient temperature (293-298 K). A controlled laboratory
environment promotes a short, reproducible thawing process; pH
changes in CSF are almost the same at 277 K and 295 K over a period
of 24 h [41]. (II) Careful mixing by inversion; excessive mechanical
perturbation leads to loss of CO2 resulting in pH changes. (III) Critical
inspection for suspended particles [3,43]; any contamination should
lead to exclusion of sample.
(IV) Addition of phosphate buffer (Vbuffer/VCSF 1/4), pH 7.2 prepared
in Milli-Q water, containing NaN3 and TSP-d4. Sample must contain ( )
10% (v/v) D2O to provide a lock signal.
Final concentrations: 50 mM NaH2PO4 / K2HPO4
(molar ratio 1/2.7)
0.02% ( w/v) NaN3
0.5 mM TSP-d4
(V) Gentle mixing by inversion, followed by transfer to NMR tube.
(VI) Storage: pending measurement, samples should be refrigerated 
and stored at a constant temperature ( 277 -279 K).
Figure 2. Proposed CSF sample preparation workflow detailing key aspects of sample handling and
pH cont ol (buffer composition described in step IV).
We carried out an NMR study on a small cohort of CSF samples (n = 23) and observed an excellent
buffer performance, with a reprod cible effect on hemical shift/peak shape. The measured pH fter
addition of buffer was 7.52 ± 0.16 (range = 7.36–7.68). Exc rpts of 1H NMR spectra of ten representative
CSF sampl s are shown in Figure 3 demonstrating excellent li nment of chemical shif metabolites
known to be (strongly) d pendent on sample pH. Leveling alterations in the i ization equilibria of
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metabolites induced by pH and salinity leads to the observed chemical shift consistency of metabolite
peaks. Following data acquisition, we monitored the pH of several samples (stored at 277 K) over three
days and did not observe significant pH changes.
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Figure 3. Stack plot of two spectral regions of the proton spectra of 10 CSF samples prepared as
described in text showing consistency of metabolite resonances typically affected by differences in
ionic strength and pH (600 MHz, 298 K, phosphate buffer 50 mM, pH 7.30–7.69, 10% D2O, line
broadening = 0.5 Hz). Note: For compound abbreviations, see Table 2.
The quality of the recorded spectra from samples of this small cohort, prepared according to the
experimental protocol described above, allowed for the identification of thirty-eight metabolites (MSI,
level 2) [55] across all spectra. The concentration estimates of metabolites of one of the pooled samples
(see below) derived from peak integration are given in Table 2.
In some of the 23 samples, possible non-endogenous contaminants (i.e., ethanol and/or isopropanol)
were identified and we determined their concentration in a few cases (Supplementary Materials
Figure S3). Their presence seems to be linked to sample collection and sterilization during sample
collection at hospital sites. Detection of ethanol in CSF might be of endogenous and/or exogenous
origin [56], but our findings suggest an exogenous origin, even though we could not rule out lower
levels of ethanol being masked by the application of skin disinfectant. In some samples we also noticed
the presence of caffeine/xanthine (Table 2). To our knowledge, the detection of caffeine by 1H NMR was
previously not reported in studies analyzing human CSF, though it has been detected by LC/MS [57].
We identified peaks with chemical shifts that match those of caffeine (δ = 7.891, 3.944, 3.519 and
3.339 ppm) when compared to literature values (Supplementary Materials, Figure S4). Spectral profiling
yielded a concentration range of 2.3–15.6 µM. The assignment was marked as ‘tentative’ because
xanthine only had one peak with a chemical shift very similar to the one of caffeine; in cases where the
peak at δ = 7.891 ppm displayed larger line widths, it is likely that both compounds were present.
Our findings described above, shed light on possible sources of contaminants and underscore the
importance of accurate control/standardization of pre-analytical factors (e.g., sample collection, storage
and sample preparation) for yielding reliable data for statistical evaluation. With this in mind, we were
interested to know whether an inherently quantitative NMR analysis could provide insights to unravel
the processes causing sample decay, and thereby identify potential markers of CSF degradation.
Two pooled CSF samples, prepared following the proposed procedure, were used to examine
sample temperature stability and their degradation as a function of time. Both samples were pooled
from remainders of different aliquots of unique CSF samples. One sample was stored at 277 K
(‘LT’ = low temperature sample), the other one at 294 K (‘RT’ = room temperature sample) and both
were monitored for several days. Sample pH was determined, and spectra of each sample were
acquired at different points in time. The different temperatures address two common scenarios in
NMR-based metabolomics studies: (1) storage of samples while queued for acquisition (i.e., in a
cooling rack), and/or (2) during possible delays at room temperature prior to measurement. Jointly,
this allowed the analysis of degradation pathways for certain metabolite classes.
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In the ‘LT’ sample, the pH measured after sample preparation was 7.30 and it remained unchanged
after 2.5 h. Moreover, at t = 96 h it was only slightly higher (i.e., pH = 7.56). The time evolution of
metabolites concentrations of the ‘LT’ sample shows little variance within the first 48 h of storage
(Supplementary Materials, Table S1). While stored for this time span at 277 K, acquisition time at
room temperature totaled 150 min. Spectral features remained almost unchanged (Supplementary
Materials, Figure S5). During the observation period of 48 h relative metabolite concentrations of most
profiled metabolites (i.e., 89% of the total number of metabolites) deviated by less than 8.5%. Only four
metabolites (i.e., acetoacetate, dimethylamine, histidine, TMAO) present in the low concentration
range (c < 7 µM) had larger deviations of 10–16% (that are likely the result of quantification uncertainty
at low concentration).
As expected, the non-refrigerated storage of the ‘RT’ sample led to larger compositional changes
caused by degradation in a contrastable storage interval of 52 h at constant temperature. Percent
metabolite concentration changes range from increased levels in acetate (531%), pyroglutamate
(113%) or dimethylamine (71%) to decreased levels in ascorbate (100%), pyruvate (86%) or fructose
(21%; Supplementary Materials, Table S2). Prolonged storage of ‘RT’ sample (i.e., exceeding
52 h) is accompanied by further changes. Two metabolites could not be detected after storage
(ascorbate and hypoxanthine), and other metabolite levels already decreasing at 52 h continued to
fall (pyruvate, fructose and threonine) while most other amino acid derivatives (leucine, isoleucine,
2-hydroxyisovalerate, valine, 2-hydroxybutyrate and alanine) followed this trend after prolonged
storage. Surprisingly, 14 metabolite levels (e.g., acetone, citrate, creatine, creatinine, dimethyl sulfone,
formate, methanol, histidine and myo-inositol) remained almost unchanged during the 100-h long
observation period.
To more accurately compare the entire degradation process in the two samples stored at different
temperatures, the full-resolution spectral data was subjected to a partial-least squares (PLS) regression
analysis. Two separate PLS models (Figure 4) were built by regressing the Pareto-scaled spectral data
with respect to time (‘RT’ t(h) = 0, 2, 20, 52, 100; ‘LT’ t(h) = 48, 96, 143, 505).
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samples. (a) Table of partial-least squares (PLS) model performance and quality parameters. (b) 1H NMR
spectra of the ‘RT’ sample acquired at different time intervals. (c) (left) Cross-validated predictions for
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sample ‘RT’, and (right) loading plot derived from the PLS model of sample ‘RT’. (d) (left) Cross
validated predictions for sample ‘LT’, and (right) loading plot derived from PLS model of sample ‘LT’.
Note: For compound abbreviations, see Table 2; here: * = VAL, LEU, aHBA and bHMB; # = regions
where signals of ethanol/isopropanol were deleted.
Model complexity was optimized by leave-one-out cross-validation, and both models were
computed with one PLS component only. The performance and quality parameters of the PLS
models are presented in Figure 4a. The proportion of variance in the spectral data explained
(indicating goodness of fit) by each model was about 60%, R2X = 0.633 (‘RT’) and 0.596 (‘LT’),
and close to 100% for the response variable, R2Y = 0.994 (‘RT’) and 0.991 (‘LT’). Each model’s predicted
variation Q2 (i.e., goodness of predictability) was high, 0.905 in the ‘RT’, and 0.931 in the ‘LT’ model.
The cross-validated predictions Y(pred) versus measured Y-variables Y(var) for each model, ‘RT’ and
‘LT’ respectively, with root-mean-square errors of estimation (RMSEE) of 3.81 and 24.1 are shown on
the left in Figure 4c,d; respectively and the diagonal in each plot represents the target line.
Spectral features that are correlated with the modeled changes occurring in each sample, can be
visualized and identified in the back-transformed loading plot (Figure 4c,d (right)), showing the
covariance cov(t,X) between the predictive score t and the centered X-variables (spectral data),
colored according to the absolute value of the correlation loading cor(t,X). Spectral features that are
correlated with the modeled changes occurring in each sample, can be visualized and identified in
the back-transformed loading plot (Figure 4c,d (right)), showing the covariance cov(t,X) between the
predictive score t and the centered X-variables (spectral data), colored according to the absolute value
of the correlation loading cor(t,X). Features that show high absolute correlation loadings have high
model influence. The covariance and correlation structure between predictive score and spectral data
looks very similar in both models (Figure 4c,d (left)), apart from some derivative effects in the loading
plot of the ‘LT’ sample, resulting from line shape artifacts and positional noise accompanying the
storage over 21 days. Spectral features, i.e., metabolites, that have high model influence were identified
to be, e.g., ascorbic acid, threonine, fructose, glycine, dimethylamine, pyruvate, pyroglutamate, acetate,
lysine and alanine.
A group of 12 metabolites was selected, exhibiting high correlations and loadings in the predictive
component of the PLS model of the ‘RT’ sample, indicating variance in the levels of those metabolites
in the observed time interval. The relative concentration levels of those metabolites (Table S2) obtained
at varying intervals are presented in Figure 5 and exhibited noticeable changes: most metabolite
levels decreased because of decomposition with the exception of acetate and pyroglutamate whose
levels increased.
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The di tinct chang s in the metabolite levels of a e ate a d pyruvate, as well as ascorbate in the
‘RT’ sample (Figure 4b) were further investigated by statistical total correlation spectroscopy analysis
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(i.e., STOCSY, Supplementary Materials, Figure S6). Using the acetate peak (δ = 1.937 ppm) as a driver,
very high correlations was observed with both pyruvate (r2 ≈ 1, δ = 2.379 ppm) and ascorbic acid
(r2 ≈ 0.8, δ = 4.528, 4.035 and 3.787 ppm). Relative concentration changes ∆cPYR~∆cAA were highly
correlated for a duration of 20 h, supporting a putative interconversion (Supplementary Materials,
Table S3).
After twenty hours of storage at room temperature though, the relative concentration change of
pyruvate was smaller than that of acetate (Figure 5). Upon consumption of pyruvate (t > 100 h), acetate
concentration continued to rise, possibly due to bacterial activity not fully suppressed by sodium azide.
Additionally, breakdown of lower concentrated N-acetylated compounds present in solution may
also be responsible for releasing acetate. The correlation of this process (as picked up by the STOCSY
analysis) to ascorbate can be explained by the shared linear dependency of the overall degradation
(i.e., change in intensity).
A comparable relative concentration change of acetate and pyruvate was observed in the ‘LT’
sample after 21 days (505 h) of storage at 277 K, highlighting the commonality of this degradation
pathway across these two pooled samples, which is also the result of the PLS model comparison.
While several metabolite classes only exhibited minor changes in their concentration levels in both
samples in a moderate observation and storage period (48/52 h), at room temperature clear signs of
active degradation are observable. Our findings strongly indicate to exercise caution when considering
any of the affected metabolites (e.g., acetate, pyruvate and ascorbic acid) as markers. Particularly
ascorbic acid is susceptible to oxidative degradation, especially at room temperature. In one study three
metabolites were found to be significant in the differentiation of the studied groups [7], while another
one excluded pyruvate and acetate, as well as acetone because of unspecified apparent batch effects [20].
The changes in acetate and pyruvate concentrations found in our experiments under both storage
conditions may indicate potential ongoing enzymatic activity causing the interconversion that is
part of the TCA (tricarboxylic acid) cycle. In a small cohort of CSF samples that were stored at low
temperature for one month, the changes in the levels of acetate and pyruvate (Supplementary Materials,
Table S4) were found to be statistically significant (Supplementary Materials, Figure S7), supporting
metabolite interconversion, while the significant rise of acetate in the ‘RT’ sample is likely caused by
the breakdown of low-concentrated macromolecules and of N-acetylated compounds. Observations
supporting this causal relationship of ongoing aerobic and anaerobic metabolic processes were made
elsewhere [42]. Further research is necessary to delineate the dependency of their decay. The uniform
approach presented in this work may help to validate biomarker research in CSF samples.
3. Materials and Methods
3.1. Materials and Reagents
All compounds used for the model solution (sodium acetate, l-alanine, trisodium citrate, sodium
formate, glucose, l-glutamine, sodium lactate, methanol, l-phenylalanine, l-histidine, l-tyrosine,
l-threonine and l/d-valine) as well as sodium azide, sodium phosphate monobasic and potassium
phosphate dibasic were purchased from Sigma-Aldrich and were used without further purification.
D2O and deuterated sodium 3-trimethylsilylpropionate (TSP-d4) used as a chemical shift reference
were purchased from Cambridge Isotope Laboratories.
3.2. CSF Collection
The cerebrospinal fluid (CSF) samples analyzed in this study were obtained from a local biomaterial
bank. The study was approved by an institutional review board (Ethikausschuss 2 Charité; BIH CRG
2a, EA2/118/15). Informed consent was obtained from all individuals prior to participating in this study.
Aliquots of 0.5–1 mL CSF per subject were collected between 9 and 12 a.m. Patients did not fast prior
to lumbar puncture. CSF was collected in sterile polypropylene vials and centrifuged immediately
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(10 min, 3000× g at RT). The supernatant was aliquoted in cryotubes, frozen in liquid nitrogen max.
30 min after lumbar puncture and subsequently stored at 193 K until 1H NMR analysis.
3.3. Preparation of Model Solution and CSF Samples for NMR Studies
3.3.1. Model Solution
The stock solution was prepared in Milli-Q water and contained sodium acetate (0.108 mM,
l-alanine (0.091 mM), trisodium citrate (0.307 mM), sodium formate (0.135 mM), glucose (2.50 mM),
l-glutamine (0.599 mM), l-histidine (0.029 mM), sodium lactate (1.41 mM), methanol (0.247 mM),
l-threonine (0.073 mM), l/d-valine (0.067 mM), l-tyrosine (0.033 mM) and l-phenylalanine (0.019 mM).
The model solution samples were prepared as follows: At pH 9.5, 500 µL stock solution, 130 µL Milli-Q
water (containing 2.69 mM TMSP-d4), and 70 µL D2O, pH adjusted by addition of sodium hydroxide
solution; at pH 7.5, 500 µL stock solution, 130 µL phosphate buffer solution (see description below)
and 70 µL of D2O.
3.3.2. CSF Samples
CSF samples (n = 23) and two samples obtained by pooling remainders of those 23 unique samples
were prepared for NMR analysis. CSF aliquots were allowed to thaw at room temperature (294 K),
typically requiring about 5 min. The thawed aliquot was mixed by repeated inversion. 500 µL of CSF
were transferred to a 1.5 mL standard Eppendorf tube and phosphate buffer solution (130 µL, 270 mM,
pH 7.19) prepared from a mixture of K2HPO4 and NaH2PO4 in Milli-Q water, containing 0.11% (w/v)
NaN3 and 2.69 mM deuterated sodium 3-trimethylsilylpropionate (TSP-d4) were added along with
70 µL of D2O. Upon sample mixing by repeated inversion, the mixture (700 µL) was transferred into
a 5 mm NMR tube. Final phosphate concentration in each sample was 50 mM, and final TSP-d4
reference concentration was 0.5 mM. The pH of a prepared sample was determined prior and after
data acquisition with a glass electrode to monitor the performance of the proposed buffer composition.
Uncorrected pH values are reported. Samples were kept at 277 K while queued for acquisition.
3.4. NMR Spectroscopy
All 1H NMR spectra were collected on a 600 MHz Avance II+ spectrometer (Bruker
BioSpin, Karlsruhe, Germany) equipped with a 5 mm TBI z-gradient pulsed-field gradient (PFG)
room-temperature probe. One-dimensional 1H NMR spectra were acquired at 298 K using the first
increment of a gradient enhanced nuclear Overhauser effect spectroscopy (NOESY) pulse sequence
(noesypresat) with presaturation during a relaxation delay of 4 s and a mixing time of 10 ms for efficient
water suppression. A total of 128 scans with a spectral width of 12,335 or 9590 Hz and 64k data points
were recorded. Prior Fourier transformation, FID was multiplied by an exponential window function
with a line-broadening factor of 0.5 Hz (if not stated otherwise), phased using zero-order terms (where
possible), and referenced to the internal standard TSP-d4 (δ = 0.0 ppm). All NMR spectra were visually
inspected for artifacts.
3.5. Chemometric Analysis
3.5.1. Metabolic Fingerprinting and Profiling
One-dimensional proton spectra were baseline corrected, and 38 metabolites profiled using the
database stored in Chenomx NMR suite 8.4 (Chenomx Inc., Edmonton, AB, Canada, 2018). For PLS
regression, full resolution spectra in the spectral range of 0.5–10 ppm were used. The region containing
the residual water signal and urea (4.7–6.4 ppm), in addition to the regions containing resonances
of known contaminant signals (i.e., ethanol/isopropanol, 1.11–1.24 ppm and 3.63–3.695 ppm) were
excluded. Spectra were baseline corrected and normalized to the total intensity.
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3.5.2. Statistical Analysis
Data matrix was imported into the R software. Statistical correlation analysis (STOCSY) [58] was
used to aid the identification of ambiguous metabolites. STOCSY and PLS analysis were performed
using “R” (cran.r-project.org), release 3.6.1 for Mac.
4. Conclusions
A simple and efficient protocol for the preparation of CSF NMR samples was devised allowing
high throughput analysis and general applicability. Our investigation highlights the need for efficient
pH control, and the suggested approach (i.e., employing a buffer), eliminates the necessity to adjust
and check pH values of each individual sample.
Overall, our findings suggest that following sample preparation according to the proposed
protocol, maintaining a biological pH and keeping samples refrigerated while queued for acquisition,
allows even sensitive and low concentrated metabolites to remain stable for up to 48 h. In addition,
we presented a detailed experimental description of CSF sample degradation using an NMR-based
chemometric approach. Our observations support previous findings of changes in the levels of
acetate, pyruvate and ascorbic acid associated with the duration of storage and we have quantified
these (and other) changes. Previously documented observations [59], mainly those stating general
sample instability, cannot be supported by our data when the samples are prepared according to the
proposed protocol.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/6/251/s1:
Table S1: List of metabolites and concentrations [µM] determined in the pooled CSF sample ‘LT’ at the specified
times of storage, Table S2: List of metabolites and concentrations [µM] determined in the pooled CSF sample ‘RT’
at the specified times of storage, Table S3: Relative concentration changes for pyruvate (PYR), and acetate (AA),
with r2 ≈ 1 for different storage conditions in the pooled samples, Table S4: Relative metabolite concentrations of
acetate and pyruvate determined via peak integration in 12 representative samples, Figure S1: 1H NMR spectrum
showing all resonances and composition of the prepared model solution, Figure S2: Aromatic region of two 1H
NMR spectra of the same CSF sample acquired with and without imidazole as an internal pH reference, Figure S3:
Comparison of relative ethanol and isopropanol concentrations in replicated samples of four subjects, Figure S4:
Supporting data for the assignment of caffeine in the analyzed CSF samples, Figure S5: Stacked plot of five 1H
NMR spectra of sample ‘LT’ measured at the specified times after preparation, Figure S6: 1D STOCSY plot of
spectral data (‘RT’ sample), Figure S7: Normality distribution and significance testing of acetate and pyruvate
metabolite levels in 12 unique samples.
Author Contributions: Conceptualization of the project by M.K.P., O.P. and N.E.S., C.S. and O.P. provided
and collected CSF samples. Preliminary NMR experiments were performed by E.V. with the help of N.E.S.
and M.D.D.-H., preparation of samples for NMR analysis and further NMR experimental work, as well as
implementation of software by B.A. with help of M.D.D.-H. Investigation and formal analysis by B.A. and M.D.D.-H.,
assisted by N.E.S. Preparation of the original draft, as well as review and editing were done by B.A., M.D.D.-H.
and N.E.S. M.D.D.-H. and N.E.S. supervised all stages of experiments and oversaw all activities. All authors have
read and approved the final manuscript.
Funding: The authors thank the Focus Area “DynAge” for the financial support of the study and the Department
of Organic Chemistry (University of Cologne) for financial support for B.A. Acquisition of the 600 MHz NMR
spectrometer was supported by a ‘HBFG’ grant (HBFG 111/602-1) of the Federal State of North Rhine-Westphalia
and the Deutsche Forschungsgemeinschaft (DFG).
Acknowledgments: The authors thank Kathrin König, Daniela Naumann, Linda Jütten, Stefan Kuhn and Philip
Hegemann of the NMR facility of the University of Cologne for their technical support. M.D.D.-H. and N.E.S. are
very grateful to the University of Cologne as participants of the JobSharing project for their support.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Milhorat, T.H.; Hammock, M.K. Cerebrospinal fluid as reflection of internal milieu of brain. In Neurobiology
of Cerebrospinal Fluid, 1st ed.; Wood, J.H., Ed.; Springer: Boston, MA, USA, 1983; pp. 1–23.
Metabolites 2020, 10, 251 12 of 15
2. Holmes, E.; Tsang, T.M.; Huang, J.T.J.; Leweke, F.M.; Koethe, D.; Gerth, C.W.; Nolden, B.M.; Gross, S.;
Schreiber, D.; Nicholson, J.K.; et al. Metabolic profiling of CSF: Evidence that early intervention may impact
on disease progression and outcome in schizophrenia. PLoS Med. 2006, 3, e327. [CrossRef] [PubMed]
3. Lutz, N.W.; Cozzone, P.J. Metabolic profiling in multiple sclerosis and other disorders by quantitative analysis
of cerebrospinal fluid using nuclear magnetic resonance spectroscopy. Curr. Pharm. Biotechnol. 2011, 12,
1016–1025. [CrossRef] [PubMed]
4. Blasco, H.; Nadal-Desbarats, L.; Pradat, P.-F.; Gordon, P.H.; Antar, C.; Veyrat-Durebex, C.; Moreau, C.;
Devos, D.; Mavel, S.; Emond, P.; et al. Untargeted 1H-NMR metabolomics in CSF: Toward a diagnostic
biomarker for motor neuron disease. Neurology 2014, 82, 1167–1174. [CrossRef] [PubMed]
5. Öhman, A.; Forsgren, L. NMR metabonomics of cerebrospinal fluid distinguishes between Parkinson’s
disease and controls. Neurosci. Lett. 2015, 594, 36–39. [CrossRef]
6. Sinclair, A.J.; Viant, M.R.; Ball, A.K.; Burdon, M.A.; Walker, E.A.; Stewart, P.M.; Rauz, S.; Young, S.P.
NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases–A diagnostic
tool? NMR Biomed. 2009, 23, 123–132. [CrossRef]
7. Blasco, H.; Corcia, P.; Moreau, C.; Veau, S.; Fournier, C.; Vourc’h, P.; Emond, P.; Gordon, P.; Pradat, P.F.;
Praline, J.; et al. 1H-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis.
PLoS ONE 2010, 5, e13223. [CrossRef]
8. Dunne, V.G.; Bhattachayya, S.; Besser, M.; Rae, C.; Griffin, J.L. Metabolites from cerebrospinal fluid in
aneurysmal subarachnoid haemorrhage correlate with vasospasm and clinical outcome: A pattern-recognition
1H NMR study. NMR Biomed. 2005, 18, 24–33. [CrossRef]
9. Nogueras, L.; Gonzalo, H.; Jové, M.; Sol, J.; Gil-Sanchez, A.; Hervás, J.V.; Valcheva, P.; Gonzalez-Mingot, C.;
Solana, M.J.; Peralta, S.; et al. Lipid profile of cerebrospinal fluid in multiple sclerosis patients: A potential
tool for diagnosis. Sci. Rep. 2019, 9, 11313. [CrossRef]
10. Seyer, A.; Boudah, S.; Broudin, S.; Junot, C.; Colsch, B. Annotation of the human cerebrospinal fluid lipidome
using high resolution mass spectrometry and a dedicated data processing workflow. Metabolomics 2016, 12, 91.
[CrossRef]
11. Feinkohl, I.; Schipke, C.G.; Kruppa, J.; Menne, F.; Winterer, G.; Pischon, T.; Peters, O. Plasma Amyloid
concentration in alzheimer’s disease: Performance of a high-throughput amyloid assay in distinguishing
alzheimer’s disease cases from controls. J. Alzheimer’s Dis. 2020, 74, 1285–1294. [CrossRef]
12. Petroff, O.A.C.; Yu, R.K.; Ogino, T. High-Resolution Proton Magnetic Resonance Analysis of Human
Cerebrospinal Fluid. J. Neurochem. 1986, 47, 1270–1276. [CrossRef] [PubMed]
13. Rosenling, T.; Stoop, M.P.; Smolinska, A.; Muilwijk, B.; Coulier, L.; Shi, S.; Dane, A.; Christin, C.; Suits, F.;
Horvatovich, P.L.; et al. The impact of delayed storage on the measured proteome and metabolome of human
cerebrospinal fluid. Clin. Chem. 2011, 57, 1703–1711. [CrossRef]
14. Cruz, T.; Balayssac, S.; Gilard, V.; Martino, R.; Vincent, C.; Pariente, J.; Malet-Martino, M. 1H NMR analysis
of cerebrospinal fluid from alzheimer’s disease patients: An example of a possible misinterpretation due to
non-adjustment of pH. Metabolites 2014, 4, 115–128. [CrossRef] [PubMed]
15. Lewczuk, P.; Kornhuber, J.; Wiltfang, J. The German competence net dementias: Standard operating
procedures for the neurochemical dementia diagnostics. J. Neural Transm. 2006, 113, 1075–1080. [CrossRef]
16. Kirwan, J.A.; Brennan, L.; Broadhurst, D.; Fiehn, O.; Cascante, M.; Dunn, W.B.; Schmidt, M.A.; Velagapudi, V.
Preanalytical processing and biobanking procedures of biological samples for metabolomics research:
A white paper, community perspective (for “Precision Medicine and Pharmacometabolomics Task
Group”—The Metabolomics Society Initiative). Clin. Chem. 2018, 64, 1158–1182. [CrossRef] [PubMed]
17. Teunissen, C.E. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.
Neurology 2009, 73, 1914–1922. [CrossRef] [PubMed]
18. Chatterji, T.; Singh, S.; Sen, M.; Singh, A.K.; Maurya, P.K.; Husain, N.; Srivastava, J.K.; Mandal, S.K.; Roy, R.
Comprehensive 1H NMR metabolic profiling of body fluids for differentiation of meningitis in adults.
Metabolomics 2016, 12, 1–14. [CrossRef]
19. Mason, S.; Reinecke, C.J.; Solomons, R.; Wevers, R.A.; Engelke, U.F.H. 1H NMR spectral identification of
medication in cerebrospinal fluid of pediatric meningitis. J. Pharm. Biomed. Anal. 2017, 143, 56–61. [CrossRef]
Metabolites 2020, 10, 251 13 of 15
20. Zielman, R.; Postma, R.; Verhoeven, A.; Bakels, F.; van Oosterhout, W.P.; Meissner, A.;
van den Maagdenberg, A.M.; Terwindt, G.M.; Mayboroda, O.A.; Ferrari, M.D. Metabolomic changes
in CSF of migraine patients measured with 1H-NMR spectroscopy. Mol. Biosyst. 2016, 12, 3674–3682.
[CrossRef]
21. Meissner, A.; van der Plas, A.A.; van Dasselaar, N.T.; Deelder, A.M.; van Hilten, J.J.; Mayboroda, O.A.
1H-NMR metabolic profiling of cerebrospinal fluid in patients with complex regional pain syndrome–related
dystonia. Pain 2014, 155, 190–196. [CrossRef]
22. Paskevich, S.I.; Molchanov, M.V.; Timchenko, M.A.; Kutyshenko, V.P. Sample pretreatment of brain tissues
and cerebrospinal fluid for NMR investigations. J. Anal. Chem. 2013, 68, 862–870. [CrossRef]
23. Kork, F.; Gentsch, A.; Holthues, J.; Hellweg, R.; Jankowski, V.; Tepel, M.; Zidek, W.; Jankowski, J. A biomarker
for severity of Alzheimer’s disease: 1H-NMR resonances in cerebrospinal fluid correlate with performance
in mini-mental-state-exam. Biomarkers 2012, 17, 36–42. [CrossRef] [PubMed]
24. Hsu, W.H.; Shen, Y.C.; Shiao, Y.J.; Kuo, C.H.; Lu, C.K.; Lin, T.Y.; Ku, W.C.; Lin, Y.L. Combined proteomic and
metabolomic analyses of cerebrospinal fluid from mice with ischemic stroke reveals the effects of a Buyang
Huanwu decoction in neurodegenerative disease. PLoS ONE 2019, 14, e0209184. [CrossRef]
25. Kim, H.H.; Jeong, I.H.; Hyun, J.S.; Kong, B.S.; Kim, H.J.; Park, S.J. Metabolomic profiling of CSF in
multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. PLoS ONE
2017, 12, e0181758. [CrossRef] [PubMed]
26. Li, Z.; Du, B.; Li, J.; Zhang, J.; Zheng, X.; Jia, H.; Xing, A.; Sun, Q.; Liu, F.; Zhang, Z. Cerebrospinal fluid
metabolomic profiling in tuberculous and viral meningitis: Screening potential markers for differential
diagnosis. Clin. Chim. Acta 2017, 466, 38–45. [CrossRef]
27. Gray, E.; Larkin, J.R.; Claridge, T.D.; Talbot, K.; Sibson, N.R.; Turner, M.R. The longitudinal cerebrospinal
fluid metabolomic profile of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2015, 16,
456–463. [CrossRef] [PubMed]
28. Engelke, U.F.H.; Tangerman, A.; Willemsen, M.A.A.P.; Moskau, D.; Loss, S.; Mudd, S.H.; Wevers, R.A.
Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional 1H and
two-dimensional 1H-13C NMR. NMR Biomed. 2005, 18, 331–336. [CrossRef] [PubMed]
29. Mason, S.; van Furth, A.M.; Mienie, L.J.; Engelke, U.F.; Wevers, R.A.; Solomons, R.; Reinecke, C.J.
A hypothetical astrocyte–microglia lactate shuttle derived from a 1H NMR metabolomics analysis of
cerebrospinal fluid from a cohort of South African children with tuberculous meningitis. Metabolomics
2015, 11, 822–837. [CrossRef] [PubMed]
30. Mercier, P.; Lewis, M.J.; Chang, D.; Baker, D.; Wishart, D.S. Towards automatic metabolomic profiling
of high-resolution one-dimensional proton NMR spectra. J. Biomol. NMR 2011, 49, 307–323. [CrossRef]
[PubMed]
31. Murgia, F.; Lorefice, L.; Poddighe, S.; Giuseppe, F.; Secci, M.A.; Marrosu, M.G.; Cocco, E.; Atzori, L.
Multi-platform characterization of cerebrospinal fluid and serum metabolome of patients affected by
relapsing–Remitting and primary progressive multiple sclerosis. J. Clin. Med. 2020, 9, 863. [CrossRef]
[PubMed]
32. Lin, H.T.; Cheng, M.L.; Lo, C.J.; Lin, G.; Lin, S.F.; Yeh, J.T.; Ho, H.Y.; Lin, J.R.; Liu, F.C. 1H Nuclear Magnetic
Resonance (NMR)-based cerebrospinal fluid and plasma metabolomic analysis in type 2 diabetic patients
and risk prediction for diabetic microangiopathy. J. Clin. Med. 2019, 8, 874. [CrossRef]
33. Vignoli, A.; Paciotti, S.; Tenori, L.; Eusebi, P.; Biscetti, L.; Chiasserini, D.; Scheltens, P.; Turano, P.; Teunissen, C.;
Luchinat, C.; et al. Fingerprinting alzheimer’s disease by 1 H nuclear magnetic resonance spectroscopy of
cerebrospinal fluid. J. Proteome Res. 2020, 19, 1696–1705. [CrossRef]
34. Jääskeläinen, O.; Hall, A.; Tiainen, M.; van Gils, M.; Lötjönen, J.; Kangas, A.J.; Helisalmi, S.; Pikkarainen, M.;
Hallikainen, M.; Koivisto, A.; et al. Metabolic profiles help discriminate mild cognitive impairment from
dementia stage in alzheimer’s disease. J. Alzheimer’s Dis. 2020, 74, 277–286. [CrossRef] [PubMed]
35. Podlecka-Pie˛towska, A.; Kacka, A.; Zakrzewska-Pniewska, B.; Nojszewska, M.; Zieminska, E.;
Chalimoniuk, M.; Toczylowska, B. Altered cerebrospinal fluid concentrations of hydrophobic and hydrophilic
compounds in early stages of multiple sclerosis—Metabolic profile analyses. J. Mol. Neurosci. 2019, 69,
94–105. [CrossRef] [PubMed]
Metabolites 2020, 10, 251 14 of 15
36. Jukarainen, N.M.; Korhonen, S.P.; Laakso, M.P.; Korolainen, M.; Niemitz, M.; Soininen, P.; Tuppurainen, K.;
Vepsäläinen, J.; Pirttilä, T.; Laatikainen, R. Quantification of 1H NMR spectra of human cerebrospinal fluid:
A protocol based on constrained total-line-shape analysis. Metabolomics 2008, 4, 150–160. [CrossRef]
37. French, C.D.; Willoughby, R.E.; Pan, A.; Wong, S.J.; Foley, J.F.; Wheat, L.J.; Fernandez, J.; Encarnacion, R.;
Ondrush, J.M.; Fatteh, N.; et al. NMR metabolomics of cerebrospinal fluid differentiates inflammatory
diseases of the central nervous system. PLoS Negl. Trop. Dis. 2018, 12, e0007045. [CrossRef] [PubMed]
38. Zhang, P.; Zhang, W.; Lang, Y.; Qu, Y.; Chen, J.; Cui, L. 1H nuclear magnetic resonance-based metabolic
profiling of cerebrospinal fluid to identify metabolic features and markers for tuberculosis meningitis.
Infect. Genet. Evol. 2019, 68, 253–264. [CrossRef] [PubMed]
39. Chatterji, T.; Singh, S.; Sen, M.; Singh, A.K.; Agarwal, G.R.; Singh, D.K.; Srivastava, J.K.; Singh, A.;
Srivastava, R.N.; Roy, R. Proton NMR metabolic profiling of CSF reveals distinct differentiation of meningitis
from negative controls. Clin. Chim. Acta 2017, 469, 42–52. [CrossRef] [PubMed]
40. Siesjö, B.K. The regulation of cerebrospinal fluid pH. Kidney Int. 1972, 1, 360–374. [CrossRef] [PubMed]
41. Cunniffe, J.G.; Whitby-Strevens, S.; Wilcox, M.H. Effect of pH changes in cerebrospinal fluid specimens on
bacterial survival and antigen test results. J. Clin. Pathol. 1996, 49, 249–253. [CrossRef]
42. Levine, J.; Panchalingam, K.; McClure, R.J.; Gershon, S.; Pettegrew, J.W. Stability of CSF metabolites measured
by proton NMR. J. Neural Transm. 2000, 107, 843–848. [CrossRef] [PubMed]
43. Stoop, M.P.; Coulier, L.; Rosenling, T.; Shi, S.; Smolinska, A.M.; Buydens, L.; Ampt, K.; Stingl, C.; Dane, A.;
Muilwijk, B.; et al. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid
samples. Mol. Cell Proteomics 2010, 9, 2063–2075. [CrossRef]
44. Smolinska, A.; Attali, A.; Blanchet, L.; Ampt, K.; Tuinstra, T.; van Aken, H.; Suidgeest, E.; van Gool, A.J.;
Luider, T.; Wijmenga, S.S.; et al. NMR and Pattern Recognition Can Distinguish Neuroinflammation and
Peripheral Inflammation. J. Proteome Res. 2011, 10, 4428–4438. [CrossRef]
45. Ventrella, D.; Laghi, L.; Barone, F.; Elmi, A.; Romagnoli, N.; Bacci, M.L. Age-Related 1H NMR Characterization
of Cerebrospinal Fluid in Newborn and Young Healthy Piglets. PLoS ONE 2016, 11, e0157623. [CrossRef]
[PubMed]
46. Dujmovic, I.; Deisenhammer, F. Stability of cerebrospinal fluid/serum glucose ratio and cerebrospinal fluid
lactate concentrations over 24 h: Analysis of repeated measurements. Clin. Chem. Lab. Med. 2010, 48,
209–212. [CrossRef] [PubMed]
47. Verwaest, K.A.; Vu, T.N.; Laukens, K.; Clemens, L.E.; Nguyen, H.P.; van Gasse, B.; Martins, J.C.; van der
Linden, A.; Dommisse, R. 1H NMR based metabolomics of CSF and blood serum: A metabolic profile for a
transgenic rat model of Huntington disease. Biochim. Biophys. Acta Mol. Basis Dis. 2011, 1812, 1371–1379.
[CrossRef]
48. Beckonert, O.; Keun, H.C.; Ebbels, T.M.D.; Bundy, J.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. Metabolic
profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and
tissue extracts. Nat. Protoc. 2007, 2, 2692–2703. [CrossRef]
49. Wishart, D.S.; Lewis, M.J.; Morrissey, J.A.; Flegel, M.D.; Jeroncic, K.; Xiong, Y.; Cheng, D.; Eisner, R.;
Gautam, B.; Tzur, D.; et al. The human cerebrospinal fluid metabolome. J. Chromatogr. B 2008, 871, 164–173.
[CrossRef]
50. Mandal, R.; Guo, A.C.; Chaudhary, K.K.; Liu, P.; Yallou, F.S.; Dong, E.; Aziat, F.; Wishart, D.S. Multi-platform
characterization of the human cerebrospinal fluid metabolome: A comprehensive and quantitative update.
Genome Med. 2012, 4, 38. [CrossRef]
51. Xiao, C.; Hao, F.; Qin, X.; Wang, Y.; Tang, H. An optimized buffer system for NMR-based urinary metabonomics
with effective pH control, chemical shift consistency and dilution minimization. Analyst 2009, 134, 916–925.
[CrossRef]
52. Jiang, L.; Huang, J.; Wang, Y.; Tang, H. Eliminating the dication-induced intersample chemical-shift variations
for NMR-based biofluid metabonomic analysis. Analyst 2012, 137, 4209–4219. [CrossRef] [PubMed]
53. Maillet, S.; Vion-Dury, J.; Confort-Gouny, S.; Nicoli, F.; Lutz, N.W.; Viout, P.; Cozzone, P.J. Experimental
protocol for clinical analysis of cerebrospinal fluid by high resolution proton magnetic resonance spectroscopy.
Brain Res. Protoc. 1998, 3, 123–134. [CrossRef]
Metabolites 2020, 10, 251 15 of 15
54. Alum, M.F.; Shaw, P.A.; Sweatman, B.C.; Ubhi, B.K.; Haselden, J.N.; Connor, S.C.
4,4-Dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA), a promising universal internal standard
for NMR-based metabolic profiling studies of biofluids, including blood plasma and serum. Metabolomics
2008, 4, 122–127. [CrossRef]
55. Sansone, S.A.; Schober, D.; Atherton, H.J.; Fiehn, O.; Jenkins, H.; Rocca-Serra, P.; Rubtsov, D.V.; Spasic, I.;
Soldatova, L.; Taylor, C.; et al. Ontology working group members metabolomics standards initiative:
Ontology working group work in progress. Metabolomics 2007, 3, 249–256. [CrossRef]
56. van der Sar, S.A.; Zielman, R.; Terwindt, G.M.; van den Magdenberg, A.M.; Deelder, A.M.; Mayboroda, O.A.;
Meissner, A.; Ferrari, M.D. Ethanol contamination of cerebrospinal fluid during standardized sampling and
its effect on 1H-NMR metabolomics. Anal. Bioanal. Chem. 2015, 407, 4835–4839. [CrossRef] [PubMed]
57. Crews, B.; Wikoff, W.R.; Patti, G.J.; Woo, H.K.; Kalisiak, E.; Heideker, J.; Siuzdak, G. Variability analysis of
human plasma and cerebral spinal fluid reveals statistical significance of changes in mass spectrometry-based
metabolomics data. Anal. Chem. 2009, 81, 8538–8544. [CrossRef]
58. Cloarec, O.; Dumas, M.E.; Craig, A.; Barton, R.H.; Trygg, J.; Hudson, J.; Blancher, C.; Gauguier, D.; Lindon, J.C.;
Holmes, E.; et al. Statistical total correlation spectroscopy: An exploratory approach for latent biomarker
identification from metabolic 1H NMR data sets. Anal. Chem. 2005, 77, 1282–1289. [CrossRef]
59. Anesi, A.; Rondanelli, M.; D’Eril, G.M. Stability of neuroactive amino acids in cerebrospinal fluid under
various conditions of processing and storage. Clin. Chem. 1998, 44, 2359–2360. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
